Darzalex

Active Ingredient(s): Daratumumab
FDA Approved: * November 16, 2015
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38,[2] which is overexpressed in multiple myeloma cells.[3] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[4] Daratumumab was granted breakthrough ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Darzalex 100 mg/5ml Intravenous Injection, Solution, Concentrate

NDC: 57894-502

Labeler:

Janssen Biotech, Inc.